MUCOID EXOPOLYSACCHARIDE PSEUDOMONAS AERUGINOSA IVIG IN CYSTIC FIBROSIS

囊性纤维化中的粘液外多糖铜绿假单胞菌 IVIG

• 批准号: 6246092
• 负责人: Frank J. Accurso
• 金额: $ 1.71万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246092
• 关键词: Pseudomonas aeruginosa; bacterial polysaccharides; clinical research; clinical trials; cystic fibrosis; human subject; human therapy evaluation; immunoglobulins; immunotherapy; medical complication; opportunistic infections; respiratory infections

This randomized, double-blind, placebo-controlled, multicenter, parallel group comparison study is designed to evaluate the efficacy of chronic, passive immunotherapy employing one of two doses of a mucoid exopolysaccharide Psuedomonas aeruginose immune globulin, IV (MEP IVIG) in CF patients with endobroncial colonization by mucoid Pseudomonas aeruginosa.

这项随机、双盲、安慰剂对照、多中心、平行 本研究设计成组比较研究， 使用两种剂量的粘液之一的被动免疫疗法 产气假单胞菌胞外多糖免疫球蛋白IV（MEP IVIG） 粘液假单胞菌支气管内膜定植的CF患者 铜绿。